Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04802733 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease
A Phase 1 study of Advanced Parkinson's Disease, sponsored by BlueRock Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 3
- Study locations
NCT04802733 is a Phase 1 study of Advanced Parkinson's Disease that has completed, run by BlueRock Therapeutics. The registered enrollment target is 12 participants, below the 130-participant average among 3 other Advanced Parkinson's Disease trials with a reported enrollment target (91% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT04802733, a Phase 1 study of Advanced Parkinson's Disease, has completed, sponsored by BlueRock Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 3
- Study locations
Study Summary
This clinical trial is designed to test whether surgically injecting nerve cells that make dopamine into the brain of Parkinson's disease patients is safe, and to monitor for potential side effects.
Conditions Studied
Interventions
- BIOLOGICAL MSK-DA01
- DEVICE MSK-DA01 Cell Delivery Device
Study Locations (3)
California
- University of California Irvine - Orange
New York
- Weill Cornell Medical College - New York
Ontario
- Toronto Western Hospital - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-05-03 |
| Est. Completion | 2024-06-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04802733
The ClinicalTrials.gov registry entry for NCT04802733 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 130-participant average among 3 other Advanced Parkinson's Disease trials with a reported enrollment target (91% lower). The listed sponsor is BlueRock Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which MSK-DA01 is the first listed.
NCT04802733 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, New York, Ontario.
Frequently Asked Questions
What is clinical trial NCT04802733 about?
NCT04802733 is a clinical study titled "Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease". This clinical trial is designed to test whether surgically injecting nerve cells that make dopamine into the brain of Parkinson's disease patients is safe, and to monitor for potential side effects.
What is the current status of trial NCT04802733?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2021-05-03. Estimated completion is 2024-06-10.
What conditions does trial NCT04802733 study?
This clinical trial studies the following conditions: Advanced Parkinson's Disease.
What interventions are being tested in trial NCT04802733?
The interventions under investigation include: MSK-DA01 (BIOLOGICAL), MSK-DA01 Cell Delivery Device (DEVICE).
Who is sponsoring clinical trial NCT04802733?
This trial is sponsored by BlueRock Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04802733 being conducted?
This trial has 3 study locations across California, New York, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SAD Study in Patients With Parkinson's Disease and Motor Fluctuations
RECRUITING · Phase 1
-
Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease
COMPLETED · Phase 3
-
A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.